Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Agios Pharmaceuticals and Incyte Corporation.
Community Practice Connections™: New Wave of Progress in Cholangiocarcinoma: Optimizing Outcomes From Diagnosis to Treatment
Release Date: April 28, 2020
Expiration Date: April 28, 2021
Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of cholangiocarcinoma, with a forward-looking perspective on how new and novel agents might impact clinical practice. The epidemiology of cholangiocarcinoma, as well as the essentials of diagnosis, molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities, will be presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.
Acknowledgement of Support
This activity is supported by educational grants from Agios Pharmaceuticals and Incyte Corporation.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of cholangiocarcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with cholangiocarcinoma are invited to participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Discuss advancements in genomics and molecular markers and their influence on cholangiocarcinoma management
- Apply the latest strategies to promptly and accurately diagnose cholangiocarcinoma based on tumor location and biomarkers
- Evaluate current standard of care approaches in the clinical management of cholangiocarcinoma
- Synthesize emerging data from recent clinical trials of novel therapies for cholangiocarcinoma
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Attending Physician
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College at Cornell University
New York, NY
Disclosures: Grant/Research Support: Acta Biologica, Agios Pharmaceuticals, Array BioPharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Casi Pharmaceuticals, Celgene, Exelixis, Genentech, Halozyme Therapeutics, Inc., Incyte Corporation, Eli Lilly, MabVax Therapeutics, Novartis, Polaris Pharmaceuticals, Inc., Puma Biotechnology, QED Therapeutics, Inc., Roche; Consultant: Agios Pharmaceuticals, AstraZeneca, Bayer, BeiGene, Bioline, Bristol Myers Squibb, Celgene, CytomX Therapeutics, Debiopharm, Eisai Co., Ltd., Exelixis, Flatiron Health, Inc., Genoscience Pharma, Incyte, Ipsen, Janssen Pharmaceutica, Laboratory for Advanced Medicine, Eli Lilly, Loxo Oncology, Inc., Merck & Co., Inc., MiNA Therapeutics, Pfizer, QED Therapeutics, Redhill Biopharma Ltd., Sanofi, Silenseed, SillaJen, Sobi, Targovax, twoXAR Pharmaceuticals, Vicus Therapeutics, Yiviva.
Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AstraZeneca, Eli Lilly, Merck & Co. Inc., QED Therapeutics, Inc.; Consultant: Basilea Pharmaceutica, EMD Serono, Inc., Meclon Pharmaceuticals, OncoSil Medical, Pieris Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd.
Associate Professor of Medicine
Director, Developmental Therapeutics Program
Clinical Director, Gastrointestinal Oncology Program
Division of Oncology
Washington University School of Medicine
St Louis, MO
Disclosures: Andrea Wang-Gillam MD, PhD, has no relevant financial relationships with commercial interests.
Associate Attending Surgeon
Hepato-Pancreato-Biliary Service
Co-Director of Surgical Initiatives
David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Other: Travel for Bayer and Intuitive Surgical Inc.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
